{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:03:37Z","timestamp":1784955817065,"version":"3.55.0"},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sevasemten (EDG\u20105506) is a novel, orally bioavailable, investigational small molecule designed to selectively modulate type II fast skeletal myosin with the goal of protecting dystrophic muscle from contraction\u2010induced injury. Sevasemten is in clinical development for the treatment of Becker and Duchenne muscular dystrophy. In the current Phase 1 study (NCT05730842), eight participants were dosed with a 20\u00a0mg single oral suspension dose of sevasemten containing approximately 500 \u00b5Ci [\n                    <jats:sup>14<\/jats:sup>\n                    C] sevasemten. Blood and urine samples were collected to evaluate the pharmacokinetics (PK), oral absorption, metabolism, and excretion (AME) of sevasemten and its metabolites. A second cohort of seven\u00a0participants received a single 20 mg oral dose of sevasemten, followed 2\u00a0h later by a single dose of [\n                    <jats:sup>14<\/jats:sup>\n                    C] sevasemten administered as a single intravenous (IV) bolus with approximately 1\u00a0\u00b5Ci [\n                    <jats:sup>14<\/jats:sup>\n                    C] sevasemten to determine absolute bioavailability. Sevasemten was excreted primarily in urine (52.1%) subsequent to CYP3A\u2010mediated metabolism, and 8.89% was eliminated in the feces, for a total of 61.0% recovered over 840 h post\u2010dose. Most of the recoverable radioactivity was excreted by 576 h (24 days). However, sevasemten total radioactivity in plasma and whole blood was characterized by a very slow elimination phase of 16.1\u201320.6 days; total recovery of radioactivity was not achieved. Sevasemten was well tolerated, with no serious adverse events or adverse events leading to study discontinuation. Sevasemten has favorable PK properties for once daily administration and continues to be investigated for the treatment of Becker and Duchenne muscular dystrophies.\n                  <\/jats:p>","DOI":"10.1002\/jcph.70234","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:28:06Z","timestamp":1783056486000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Human Disposition, Metabolism, and Excretion of Sevasemten (EDG\u20105506), a Selective Modulator of Fast Myosin in Healthy Volunteers"],"prefix":"10.1002","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9008-7288","authenticated-orcid":false,"given":"Molly","family":"Madden","sequence":"first","affiliation":[{"name":"Edgewise Therapeutics, Inc.  Boulder CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Evanchik","sequence":"additional","affiliation":[{"name":"Edgewise Therapeutics, Inc.  Boulder CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lane","sequence":"additional","affiliation":[{"name":"Edgewise Therapeutics, Inc.  Boulder CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Donovan","sequence":"additional","affiliation":[{"name":"Edgewise Therapeutics, Inc.  Boulder CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Russell","sequence":"additional","affiliation":[{"name":"Edgewise Therapeutics, Inc.  Boulder CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Silverman","sequence":"additional","affiliation":[{"name":"Edgewise Therapeutics, Inc.  Boulder CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.2040-4603.2015.tb00638.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.150.5.1209"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.8.3710"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00858725"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00244.2007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00095.2015"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-1-21"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.647010"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.8.3710"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1026030"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00121296"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(88)90463-1"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.201010436"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006812004945"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16170-2"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.319"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.043638"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153837"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28444"},{"key":"e_1_2_8_21_1","volume-title":"Guidance for industry M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals","author":"US Food and Drug Administration","year":"2010"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2015.311"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70234","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70234","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:47:03Z","timestamp":1784954823000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/jcph.70234"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70234","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70234"}}